FHIR Release 3 (STU)
WorkflowThis page is part of the FHIR Specification (v3.0.2: STU 3). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions 
. Page versions: R5 R4B R4 R3
| Clinical Decision Support Work Group | Maturity Level: N/A | Ballot Status: Informative | Compartments: Not linked to any defined compartments |
Chemotherapy Regimen
{
"resourceType": "PlanDefinition",
"id": "KDN5",
"text": {
"status": "additional",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <table style=\"width: 100%;\">\n <tr>\n <td>\n <!-- link to NCCN image -->\n <div style=\"width: 200px; height: 100px; vertical-align: top;\">National Comprehensive Cancer Network</div>\n </td>\n <td>\n <h3>Chemotherapy Order Template</h3>\n <h1>Kidney Cancer</h1>\n <h2>Gemcitabine/CARBOplatin</h2>\n </td>\n <td style=\"text-align: right; vertical-align: top;\">KDN5</td>\n </tr>\n </table>\n <table style=\"width: 100%; border-top: 1px solid; border-bottom: 1px solid;\">\n <tr>\n <td style=\"width: 33%; border-right: 1px solid; vertical-align: top\">\n <h4>INDICATION:</h4>\n <p>Metastatic or Relapsed – Collecting Duct/Medullary Subtypes</p>\n </td>\n <td style=\"width: 34%; border-right: 1px solid; vertical-align: top\">\n <h4>REFERENCES:</h4>\n <ol>\n <li><a href=\"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf\">NCCN Guidelines® for Kidney Cancer. V.3.2015.</a></li>\n <li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D\">Oudard S, et al. <em>J Urol</em>. 2007;177(5):1698-702.</a><sup>\n <a href=\"http://www.example.org/OrderTemplates/PDF/appendix_E.pdf\">a</a></sup>\n </li>\n </ol>\n </td>\n <td style=\"width: 33%; vertical-align: top\">\n <h4>NCCN SUPPORTIVE CARE:</h4>\n <ol>\n <li>\n <i>Emetic Risk:</i>\n <table>\n <tr>\n <td>Day 1</td>\n <td>Moderate</td>\n </tr>\n <tr>\n <td>Day 8</td>\n <td>Low</td>\n </tr>\n </table>\n </li>\n <li>\n <i>Fever Neutropenia Risk:</i><br/>\n Refer to <a href=\"http://www.example.org/professionals/physician_gls/PDF/myeloid_growth.pdf\">NCCN Guidelines for Myeloid Growth Factors. V.2.2014</a>\n </li>\n </ol>\n </td>\n </tr>\n </table>\n <!-- same as the regimen section of the Composition resource only this version is without the style guide notes -->\n <h4>CHEMOTHERAPY REGIMEN</h4>\n <p>\n <i>21-day cycle for 6 cycles</i>\n </p>\n <ul>\n <li>Gemcitabine 1250 mg/m<sup>2</sup> IV over 30 minutes on Days 1 and 8</li>\n <li>CARBOplatin AUC 5 IV over 30 minutes on Day 1</li>\n </ul>\n </div>"
},
"contained": [
{
"resourceType": "ActivityDefinition",
"id": "1111",
"status": "draft",
"productCodeableConcept": {
"coding": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"code": "12574",
"display": "gemcitabine"
}
],
"text": "gemcitabine"
},
"dosage": [
{
"text": "1250 mg/m² IV over 30 minutes",
"timing": {
"repeat": {
"duration": 30,
"durationUnit": "min"
}
},
"route": {
"text": "IV"
},
"doseQuantity": {
"value": 1250,
"unit": "mg/m²"
}
}
]
},
{
"resourceType": "ActivityDefinition",
"id": "2222",
"status": "draft",
"productCodeableConcept": {
"coding": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"code": "40048",
"display": "Carboplatin"
}
],
"text": "CARBOplatin"
},
"dosage": [
{
"text": "AUC 5 IV over 30 minutes",
"timing": {
"repeat": {
"duration": 30,
"durationUnit": "min"
}
},
"route": {
"text": "IV"
},
"doseQuantity": {
"extension": [
{
"url": "http://example.org/fhir/AUC-dose",
"valueInteger": 5
}
]
}
}
]
}
],
"identifier": [
{
"system": "http://example.org/ordertemplates",
"value": "KDN5"
}
],
"version": "1",
"title": "Gemcitabine/CARBOplatin",
"type": {
"text": "Chemotherapy Order Template"
},
"status": "draft",
"experimental": true,
"publisher": "National Comprehensive Cancer Network, Inc.",
"approvalDate": "2016-07-27",
"lastReviewDate": "2016-07-27",
"useContext": [
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "A"
}
],
"code": {
"system": "http://example.org/fhir/CodeSystem/indications",
"code": "treamentSetting-or-diseaseStatus"
},
"valueCodeableConcept": {
"text": "Metastatic"
}
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "A"
}
],
"code": {
"system": "http://example.org/fhir/CodeSystem/indications",
"code": "disease-or-histology"
},
"valueCodeableConcept": {
"text": "Collecting Duct/Medullary Subtypes"
}
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "A"
}
],
"code": {
"system": "http://hl7.org/fhir/usage-context-type",
"code": "focus"
},
"valueCodeableConcept": {
"text": "Kidney Cancer"
}
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "B"
}
],
"code": {
"system": "http://example.org/fhir/CodeSystem/indications",
"code": "treatmentSetting-or-diseaseStatus"
},
"valueCodeableConcept": {
"text": "Relapsed"
}
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "B"
}
],
"code": {
"system": "http://example.org/fhir/CodeSystem/indications",
"code": "disease-or-histology"
},
"valueCodeableConcept": {
"text": "Collecting Duct/Medullary Subtypes"
}
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "B"
}
],
"code": {
"system": "http://hl7.org/fhir/usage-context-type",
"code": "focus"
},
"valueCodeableConcept": {
"text": "Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic"
}
}
],
"contributor": [
{
"type": "author",
"name": "Lee Surprenant"
}
],
"copyright": "All rights reserved.",
"relatedArtifact": [
{
"type": "derived-from",
"display": "NCCN Guidelines for Kidney Cancer. V.2.2016",
"url": "http://www.example.org/professionals/physician_gls/PDF/kidney.pdf"
},
{
"type": "citation",
"_type": {
"extension": [
{
"url": "http://example.org/fhir/regimenReferenceType",
"valueCode": "a"
}
]
},
"citation": "Oudard S, et al. J Urol. 2007;177(5):1698-702",
"url": "http://www.ncbi.nlm.nih.gov/pubmed/17437788"
}
],
"action": [
{
"selectionBehavior": "exactly-one",
"action": [
{
"selectionBehavior": "all",
"action": [
{
"groupingBehavior": "sentence-group",
"selectionBehavior": "exactly-one",
"action": [
{
"id": "cycle-definition-1",
"textEquivalent": "21-day cycle for 6 cycles",
"timingTiming": {
"repeat": {
"count": 6,
"duration": 21,
"durationUnit": "d"
}
},
"action": [
{
"id": "action-1",
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle",
"extension": [
{
"url": "day",
"valueInteger": 1
},
{
"url": "day",
"valueInteger": 8
}
]
}
],
"textEquivalent": "Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8",
"definition": {
"reference": "#1111"
}
},
{
"id": "action-2",
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle",
"extension": [
{
"url": "day",
"valueInteger": 1
}
]
}
],
"textEquivalent": "CARBOplatin AUC 5 IV over 30 minutes on Day 1",
"relatedAction": [
{
"actionId": "action-1",
"relationship": "concurrent-with-start"
}
],
"definition": {
"reference": "#2222"
}
}
]
}
]
}
]
}
]
}
]
}
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
®© HL7.org 2011+. FHIR Release 3 (STU; v3.0.2-11200) generated on Thurs, Oct 24, 2019 11:53+1100. QA Page
Links: Search |
Version History |
Table of Contents |
Credits |
Compare to DSTU2 |
|
Propose a change